Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Targeting neurotrophin signaling in cancer: the renaissance.

Griffin N, Faulkner S, Jobling P, Hondermarck H.

Pharmacol Res. 2018 Jul 18. pii: S1043-6618(18)30993-9. doi: 10.1016/j.phrs.2018.07.019. [Epub ahead of print] Review.

PMID:
30031169
2.

The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung.

Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, Thorne RF, Ferdoushi A, Jobling P, Walker MM, Hondermarck H.

Sci Rep. 2018 May 25;8(1):8135. doi: 10.1038/s41598-018-26408-2.

3.

Neuroproteins in Cancer: Assumed Bystanders Become Culprits.

Li X, Dun MD, Faulkner S, Hondermarck H.

Proteomics. 2018 May 9:e1800049. doi: 10.1002/pmic.201800049. [Epub ahead of print]

PMID:
29745056
4.

Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer.

Almazi JG, Pockney P, Gedye C, Smith ND, Hondermarck H, Verrills NM, Dun MD.

Proteomics Clin Appl. 2018 May;12(3):e1700121. doi: 10.1002/prca.201700121. Epub 2018 Mar 30.

5.

The Sympathetic Nervous System Drives Tumor Angiogenesis.

Hondermarck H, Jobling P.

Trends Cancer. 2018 Feb;4(2):93-94. doi: 10.1016/j.trecan.2017.11.008. Epub 2017 Dec 9.

PMID:
29458965
6.

Proteomic Profiling of Human Uterine Fibroids Reveals Upregulation of the Extracellular Matrix Protein Periostin.

Jamaluddin MFB, Ko YA, Kumar M, Brown Y, Bajwa P, Nagendra PB, Skerrett-Byrne DA, Hondermarck H, Baker MA, Dun MD, Scott RJ, Nahar P, Tanwar PS.

Endocrinology. 2018 Feb 1;159(2):1106-1118. doi: 10.1210/en.2017-03018.

PMID:
29244110
7.

Spinal Cord Injuries and Nerve Dependence in Prostate Cancer.

Rutledge A, Jobling P, Walker MM, Denham JW, Hondermarck H.

Trends Cancer. 2017 Dec;3(12):812-815. doi: 10.1016/j.trecan.2017.10.001. Epub 2017 Nov 6. Review.

PMID:
29198437
8.

Neurotrophin Receptors TrkA, p75NTR, and Sortilin Are Increased and Targetable in Thyroid Cancer.

Faulkner S, Jobling P, Rowe CW, Rodrigues Oliveira SM, Roselli S, Thorne RF, Oldmeadow C, Attia J, Jiang CC, Zhang XD, Walker MM, Hondermarck H.

Am J Pathol. 2018 Jan;188(1):229-241. doi: 10.1016/j.ajpath.2017.09.008. Epub 2017 Oct 14.

PMID:
29037860
9.

Proteogenomics Gets onto the Regulation of mRNA Decoding and Translation into Protein.

Hondermarck H.

Proteomics. 2017 Nov;17(21). doi: 10.1002/pmic.201700315.

PMID:
28990322
10.

Deficiency in outer dense fiber 1 is a marker and potential driver of idiopathic male infertility.

Hetherington L, Schneider EK, Scott C, DeKretser D, Muller CH, Hondermarck H, Velkov T, Baker MA.

Mol Cell Proteomics. 2017 Jun;16(6):1172. doi: 10.1074/mcp.A116.060343. No abstract available.

11.

MicroRNA-645 is an oncogenic regulator in colon cancer.

Guo ST, Guo XY, Wang J, Wang CY, Yang RH, Wang FH, Li XY, Hondermarck H, Thorne RF, Wang YF, Jin L, Zhang XD, Jiang CC.

Oncogenesis. 2017 May 15;6(5):e335. doi: 10.1038/oncsis.2017.37.

12.

Gelatin-albumin hybrid nanoparticles as matrix metalloproteinases-degradable delivery systems for breast cancer therapy.

Shargh VH, Hondermarck H, Liang M.

Nanomedicine (Lond). 2017 May;12(9):977-989. doi: 10.2217/nnm-2016-0419. Epub 2017 Apr 25.

PMID:
28440712
13.

Nerve Dependence: From Regeneration to Cancer.

Boilly B, Faulkner S, Jobling P, Hondermarck H.

Cancer Cell. 2017 Mar 13;31(3):342-354. doi: 10.1016/j.ccell.2017.02.005. Review.

14.

Protein interaction screening identifies SH3RF1 as a new regulator of FAT1 protein levels.

de Bock CE, Hughes MR, Snyder K, Alley S, Sadeqzadeh E, Dun MD, McNagny KM, Molloy TJ, Hondermarck H, Thorne RF.

FEBS Lett. 2017 Feb;591(4):667-678. doi: 10.1002/1873-3468.12569. Epub 2017 Feb 16.

15.

Scout-MRM: Multiplexed Targeted Mass Spectrometry-Based Assay without Retention Time Scheduling Exemplified by Dickeya dadantii Proteomic Analysis during Plant Infection.

Rougemont B, Bontemps Gallo S, Ayciriex S, Carrière R, Hondermarck H, Lacroix JM, Le Blanc JC, Lemoine J.

Anal Chem. 2017 Feb 7;89(3):1421-1426. doi: 10.1021/acs.analchem.6b03201. Epub 2017 Jan 9.

PMID:
28029036
16.

Albumin hybrid nanoparticles loaded with tyrosine kinase A inhibitor GNF-5837 for targeted inhibition of breast cancer cell growth and invasion.

Shargh VH, Hondermarck H, Liang M.

Int J Pharm. 2016 Dec 30;515(1-2):527-534. doi: 10.1016/j.ijpharm.2016.10.057. Epub 2016 Oct 25.

PMID:
27793712
17.

Deficiency in Outer Dense Fiber 1 Is a Marker and Potential Driver of Idiopathic Male Infertility.

Hetherington L, Schneider EK, DeKretser D, Muller CH, Hondermarck H, Velkov T, Baker MA.

Mol Cell Proteomics. 2016 Dec;15(12):3685-3693. Epub 2016 Oct 21. Erratum in: Mol Cell Proteomics. 2017 Jun;16(6):1172.

18.

ProNGF is a potential diagnostic biomarker for thyroid cancer.

Faulkner S, Roselli S, Demont Y, Pundavela J, Choquet G, Leissner P, Oldmeadow C, Attia J, Walker MM, Hondermarck H.

Oncotarget. 2016 May 10;7(19):28488-97. doi: 10.18632/oncotarget.8652.

19.

Antibody-targeted biodegradable nanoparticles for cancer therapy.

Shargh VH, Hondermarck H, Liang M.

Nanomedicine (Lond). 2016 Jan;11(1):63-79. doi: 10.2217/nnm.15.186. Epub 2015 Dec 11. Review.

PMID:
26654068
20.

INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.

Chi MN, Guo ST, Wilmott JS, Guo XY, Yan XG, Wang CY, Liu XY, Jin L, Tseng HY, Liu T, Croft A, Hondermarck H, Scolyer RA, Jiang CC, Zhang XD.

Oncotarget. 2015 Nov 24;6(37):39891-907. doi: 10.18632/oncotarget.5359.

21.

INPP4B is an oncogenic regulator in human colon cancer.

Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, Xi YF, Jin L, Croft A, Tseng HY, Yan XG, Farrelly M, Wang FH, Lai F, Wang JF, Li YP, Ackland S, Scott R, Agoulnik IU, Hondermarck H, Thorne RF, Liu T, Zhang XD, Jiang CC.

Oncogene. 2016 Jun 9;35(23):3049-61. doi: 10.1038/onc.2015.361. Epub 2015 Sep 28.

22.

FAT1 cadherin acts upstream of Hippo signalling through TAZ to regulate neuronal differentiation.

Ahmed AF, de Bock CE, Lincz LF, Pundavela J, Zouikr I, Sontag E, Hondermarck H, Thorne RF.

Cell Mol Life Sci. 2015 Dec;72(23):4653-69. doi: 10.1007/s00018-015-1955-6. Epub 2015 Jun 24.

PMID:
26104008
23.

Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis.

Dun MD, Chalkley RJ, Faulkner S, Keene S, Avery-Kiejda KA, Scott RJ, Falkenby LG, Cairns MJ, Larsen MR, Bradshaw RA, Hondermarck H.

Mol Cell Proteomics. 2015 Sep;14(9):2316-30. doi: 10.1074/mcp.M114.046110. Epub 2015 Jun 3.

24.

Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer.

Pundavela J, Roselli S, Faulkner S, Attia J, Scott RJ, Thorne RF, Forbes JF, Bradshaw RA, Walker MM, Jobling P, Hondermarck H.

Mol Oncol. 2015 Oct;9(8):1626-35. doi: 10.1016/j.molonc.2015.05.001. Epub 2015 May 14.

25.

Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.

Roselli S, Pundavela J, Demont Y, Faulkner S, Keene S, Attia J, Jiang CC, Zhang XD, Walker MM, Hondermarck H.

Oncotarget. 2015 Apr 30;6(12):10473-86.

26.

Docosahexaenoic acid inhibits the invasion of MDA-MB-231 breast cancer cells through upregulation of cytokeratin-1.

Blanckaert V, Kerviel V, Lépinay A, Joubert-Durigneux V, Hondermarck H, Chénais B.

Int J Oncol. 2015;46(6):2649-55. doi: 10.3892/ijo.2015.2936. Epub 2015 Mar 27.

PMID:
25825023
27.

Nerve-Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression.

Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H.

Cancer Res. 2015 May 1;75(9):1777-81. doi: 10.1158/0008-5472.CAN-14-3180. Epub 2015 Mar 20. Review.

28.

Proteogenomics: emergence and promise.

Faulkner S, Dun MD, Hondermarck H.

Cell Mol Life Sci. 2015 Mar;72(5):953-7. doi: 10.1007/s00018-015-1837-y. Epub 2015 Jan 22.

PMID:
25609363
29.

NGF and ProNGF: Regulation of neuronal and neoplastic responses through receptor signaling.

Bradshaw RA, Pundavela J, Biarc J, Chalkley RJ, Burlingame AL, Hondermarck H.

Adv Biol Regul. 2015 May;58:16-27. doi: 10.1016/j.jbior.2014.11.003. Epub 2014 Nov 20. Review.

30.

ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer.

Pundavela J, Demont Y, Jobling P, Lincz LF, Roselli S, Thorne RF, Bond D, Bradshaw RA, Walker MM, Hondermarck H.

Am J Pathol. 2014 Dec;184(12):3156-62. doi: 10.1016/j.ajpath.2014.08.009. Epub 2014 Oct 5.

PMID:
25285721
31.

Antiproliferative and apoptotic effects of the oxidative dimerization product of methyl caffeate on human breast cancer cells.

Bailly F, Toillon RA, Tomavo O, Jouy N, Hondermarck H, Cotelle P.

Bioorg Med Chem Lett. 2013 Jan 15;23(2):574-8. doi: 10.1016/j.bmcl.2012.11.009. Epub 2012 Nov 22.

PMID:
23228470
32.

Neurotrophins and their receptors in breast cancer.

Hondermarck H.

Cytokine Growth Factor Rev. 2012 Dec;23(6):357-65. doi: 10.1016/j.cytogfr.2012.06.004. Epub 2012 Jun 30. Review.

PMID:
22749855
33.

Proteome changes induced by overexpression of the p75 neurotrophin receptor (p75NTR) in breast cancer cells.

Wilmet JP, Tastet C, Desruelles E, Ziental-Gelus N, Blanckaert V, Hondermarck H, Le Bourhis X.

Int J Dev Biol. 2011;55(7-9):801-9. doi: 10.1387/ijdb.113345jw.

34.

Pro-nerve growth factor induces autocrine stimulation of breast cancer cell invasion through tropomyosin-related kinase A (TrkA) and sortilin protein.

Demont Y, Corbet C, Page A, Ataman-Önal Y, Choquet-Kastylevsky G, Fliniaux I, Le Bourhis X, Toillon RA, Bradshaw RA, Hondermarck H.

J Biol Chem. 2012 Jan 13;287(3):1923-31. doi: 10.1074/jbc.M110.211714. Epub 2011 Nov 29.

35.

Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival.

Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, Nurcombe V, Le Bourhis X, Hondermarck H.

Clin Cancer Res. 2011 Apr 1;17(7):1741-52. doi: 10.1158/1078-0432.CCR-10-1890. Epub 2011 Feb 24.

36.

Ku86 is important for TrkA overexpression-induced breast cancer cell invasion.

Lagadec C, Romon R, Tastet C, Meignan S, Com E, Page A, Bidaux G, Hondermarck H, Le Bourhis X.

Proteomics Clin Appl. 2010 Jul;4(6-7):580-90. doi: 10.1002/prca.200900148. Epub 2010 Mar 26.

PMID:
21137076
37.

Overexpression of p75(NTR) increases survival of breast cancer cells through p21(waf1).

Verbeke S, Meignan S, Lagadec C, Germain E, Hondermarck H, Adriaenssens E, Le Bourhis X.

Cell Signal. 2010 Dec;22(12):1864-73. doi: 10.1016/j.cellsig.2010.07.014. Epub 2010 Jul 24.

PMID:
20667470
38.

Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways.

Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, Le Bourhis X.

Mol Cancer. 2010 Jun 22;9:157. doi: 10.1186/1476-4598-9-157.

39.

Role of endothelial progenitor cells in breast cancer angiogenesis: from fundamental research to clinical ramifications.

Le Bourhis X, Romon R, Hondermarck H.

Breast Cancer Res Treat. 2010 Feb;120(1):17-24. doi: 10.1007/s10549-009-0686-5. Epub 2009 Dec 24. Review.

PMID:
20033768
40.

Cancer proteomics--an evolving battlefield. Conference on Cancer Proteomics 2009: Mechanistic Insights, Technological Advances & Molecular Medicine.

Collins BC, Lau TY, O'Connor DP, Hondermarck H.

EMBO Rep. 2009 Nov;10(11):1202-5. doi: 10.1038/embor.2009.222. Epub 2009 Oct 2. No abstract available.

41.

TrkA overexpression enhances growth and metastasis of breast cancer cells.

Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, Toillon RA, Oxombre B, Hondermarck H, Le Bourhis X.

Oncogene. 2009 May 7;28(18):1960-70. doi: 10.1038/onc.2009.61. Epub 2009 Mar 30.

PMID:
19330021
42.

Identification of new p53 acetylation sites in COS-1 cells.

Joubel A, Chalkley RJ, Medzihradszky KF, Hondermarck H, Burlingame AL.

Mol Cell Proteomics. 2009 Jun;8(6):1167-73. doi: 10.1074/mcp.M800487-MCP200. Epub 2009 Jan 19.

43.

The proteome of the human breast cancer cell line MDA-MB-231: Analysis by LTQ-Orbitrap mass spectrometry.

Strande V, Canelle L, Tastet C, Burlet-Schiltz O, Monsarrat B, Hondermarck H.

Proteomics Clin Appl. 2009 Jan;3(1):41-50. doi: 10.1002/prca.200800083. Epub 2008 Dec 9.

PMID:
21136935
44.

A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression.

Berteaux N, Aptel N, Cathala G, Genton C, Coll J, Daccache A, Spruyt N, Hondermarck H, Dugimont T, Curgy JJ, Forné T, Adriaenssens E.

Mol Cell Biol. 2008 Nov;28(22):6731-45. doi: 10.1128/MCB.02103-07. Epub 2008 Sep 15.

45.

Nerve growth factor: the dark side of the icon.

Hondermarck H.

Am J Pathol. 2008 Apr;172(4):865-7. doi: 10.2353/ajpath.2008.080008. Epub 2008 Mar 18. No abstract available.

46.

Proteomics of breast cancer: the quest for markers and therapeutic targets.

Hondermarck H, Tastet C, El Yazidi-Belkoura I, Toillon RA, Le Bourhis X.

J Proteome Res. 2008 Apr;7(4):1403-11. doi: 10.1021/pr700870c. Epub 2008 Feb 27. Review.

PMID:
18311906
47.

Nerve growth factor is a potential therapeutic target in breast cancer.

Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R, Nurcombe V, Le Bourhis X, Hondermarck H.

Cancer Res. 2008 Jan 15;68(2):346-51. doi: 10.1158/0008-5472.CAN-07-1183.

48.

Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells.

Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, Van Coppenolle F, Hondermarck H, Le Bourhis X.

Oncogene. 2008 Feb 28;27(10):1472-7. Epub 2007 Sep 3.

PMID:
17767197
49.

[Functional proteomics in oncology: to understand more than to describe].

Com E, Hondermarck H.

Med Sci (Paris). 2007 Mar;23 Spec No 1:27-30. Review. French.

50.

Nerve growth factor receptor TrkA signaling in breast cancer cells involves Ku70 to prevent apoptosis.

Com E, Lagadec C, Page A, El Yazidi-Belkoura I, Slomianny C, Spencer A, Hammache D, Rudkin BB, Hondermarck H.

Mol Cell Proteomics. 2007 Nov;6(11):1842-54. Epub 2007 Jul 7.

Supplemental Content

Loading ...
Support Center